Comparative Pharmacology
Head-to-head clinical analysis: ERYPED versus WYAMYCIN E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYPED versus WYAMYCIN E.
ERYPED vs WYAMYCIN E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It is a macrolide antibiotic.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
250–500 mg orally every 6 hours or 500–1000 mg intravenously every 6 hours; maximum 4 g/day.
500 mg intramuscularly or intravenously every 12 hours; or 1 gram every 24 hours for severe infections.
None Documented
None Documented
2-4 hours (prolonged to 4-6 hours in neonates and patients with hepatic impairment); requires q6h dosing for most indications.
2.5 hours (increased to 5-8 hours in neonates and up to 24-48 hours in anuria).
Primarily hepatic (biliary excretion of unchanged drug and metabolites); approximately 5% renal excretion as unchanged drug.
Primarily renal (60-80% unchanged) via glomerular filtration; biliary/fecal <5%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic